The Immunotherapy Drugs Market was worth USD 164.68 billion in 2020, and is predicted to grow to USD 276.51 billion by 2028, with a CAGR of 8.41% over the forecast period.
Immunotherapies as an additional therapy in severe COVID-19 instances, according to research investigations. Immunotherapies based on inflammatory cytokine neutralisation, immunomodulation, and passive viral neutralisation can reduce inflammation, inflammation-associated lung damage, and viral load while also avoiding ICU admission and mechanical ventilation.
Access Full report here : https://www.zionmarketresearch.com/report/immunotherapy-drugs-market
Because several businesses are actively engaged on creating immunotherapy-based medications or vaccines for COVID-19, the influence of COVID-19 on the immunotherapy drugs industry is positive. BioNTech SE is now undertaking a phase III clinical trial in healthy volunteers to examine the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in partnership with Pfizer Inc.
The increased adoption of targeted therapy over traditional therapy, the emergence of biosimilars, the rising prevalence of chronic diseases and lifestyle disorders, and the rising need for monoclonal antibodies are all contributing to the expansion of the immunotherapy pharmaceuticals market.
Furthermore, factors such as rising research collaborations, the number of research laboratories, and pharmaceutical and biotechnology companies' direct and indirect RD spending will all contribute to the market's expansion in the future years. For example, Gilead Sciences Inc. and Humanigen Inc. teamed together in 2019 to explore lenzilumab in combination with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma.
Globally, the frequency of various chronic diseases has been steadily increasing, necessitating immune-based therapy in many cases. Cancer, kidney failure, autoimmune and inflammatory illnesses, and cardiac problems are among the most common chronic diseases. According to Versus Arthritis, nearly 18 percent of persons over 45 years old in England had osteoarthritis of the knee in 2019.
Furthermore, according to a study published in the International Journal of General Medicine in 2018, mortality from many noncommunicable diseases (NCDs) or chronic diseases continues to rise globally, with a disproportionately larger impact in low-middle income countries (LMIs), with chronic diseases accounting for nearly 75% of global deaths. Several lifestyle conditions, both chronic and non-communicable, such as hypertension, diabetes, obesity, and depression, necessitate essential care while in the hospital.
For example, according to GLOBOCAN 2020 data, the total number of new cancer cases worldwide in 2020 was 9,227,484, suggesting that it had climbed to 19.3 million cases and 10 million cancer deaths. The most frequent malignancies in males are lung cancer and prostate cancer, which account for almost one-third of all male cancers.
Market expansion will be aided by current nanotechnology advancements in immunotherapy. The nanoparticles, which are smaller than 100 nanometers in size, were created to treat cancer. Active or passive drug assault, high solubility bioavailability, and multifunctionality are among the advantages provided.
Immunotherapy Drugs Market Segmentation:
The immunotherapy drugs industry, by type, is segmented into:
• Monoclonal Antibodies
• Interferons Alpha and Beta
The immunotherapy drugs industry, by application, is segmented into:
North America currently dominates the market and is expected to continue to do so during the forecast period.
Throughout the projected period, North America is expected to hold a large market share. This is attributed to an increase in the number of cancer cases, a growing geriatric population, and a growing preference for and use of immunotherapy in the region.
Cancer patients are more likely to become infected with the COVID-19 virus, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-2-CoV). As a result, researchers are working on developing viable COVID-19 treatments. The Canadian Cancer Trials Group, for example, is conducting a phase III clinical trial to see if immunising cancer patients with IMM-101 can lower the occurrence of severe respiratory and COVID-19 infections.
Over the forecast period, cancer is expected to hold a significant market share in the therapy area segment.
➛ Cancer is a disease in which the body's cells grow abnormally. More than 100 different forms of cancer exist. According to GLOBOCAN data, there were approximately 2,261,419 (11.7%) new breast cancer cases in 2020, 2,206,771 (11.4%) new lung cancer cases, and 1,931,590 (10%) new colorectum cancer cases. Breast cancer is one of every four malignancies diagnosed in women around the world. Women are more likely than men to develop colorectal, lung, cervical, and thyroid malignancies. The incidence of cancer is predicted to climb in the next years, assisting the market's expansion.
➛ For the treatment of cancer, immunotherapies come in a variety of forms. Immune checkpoint inhibitors, T-cell cell transfer, cancer vaccines, and immune system modulators are examples of immunotherapies. Many forms of cancer and their advanced stages are treated with these medicines. Rituxan, Yervoy, Adcetris, and Zevalin are some of the most commonly prescribed immunotherapy medications.
There are several main companies in the immunotherapy medications market, which is fairly fragmented and extremely competitive. Few big firms currently dominate the market in terms of market share. To acquire a competitive advantage, market participants are focusing on new product releases, RD, and expansions. Pexidartinib (TURALIO, Daiichi Sankyo) pills were approved by the US FDA in August 2019 for adult patients with symptomatic tenosynovial giant cell tumour (TGCT). The following are some of the market's significant players: AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, Novartis AG, and F. Hoffmann-La Roche AG.
Read more at : https://www.zionmarketresearch.com/news/immunotherapy-drugs-market
➜ Regeneron Pharmaceuticals Inc. got FDA approval for cemiplimab-rwlc (Libtayo), an immunotherapy medication, in February 2021 for first-line treatment of NSCLC patients with high PD-L1 expression who are not candidates for surgery or chemoradiation.
➜ The combination of ramucirumab and erlotinib was authorised by the FDA in May 2020 for the first-line treatment of non-small-cell lung cancer patients with EGFR exon 19 or exon 21 mutations.
➜ The University of Hyderabad (UoH) and the CSIR-Centre for Cellular and Molecular Biology in India worked with Vins Bioproducts Ltd to develop antibody fragment-based immunotherapy for the treatment of COVID-19 in May 2020.
➜ Durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin was approved by the US Food and Drug Administration (FDA) in March 2020 as a first-line treatment for patients with advanced-stage small-cell lung cancer (ES-SCLC).
About Us :
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.